-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
NICE has issued guidelines recommending Merck/MSD's Keytruda (pembrolizumab) as a monotherapy for the adjuvant treatment of stage 3 melanoma in adult patients with completely removed lymph nodes
guide
Melanoma is the second most common cancer in men and the third most common cancer in women
diagnosis
In the past decade, the field of melanoma has made tremendous medical advances, and immunotherapy treatment has become an indispensable part of it
immunity
Before adjuvant therapy became an available option for some patients, the standard postoperative practice for melanoma was active surveillance, closely monitoring patients to check for cancer recurrence
According to the Phase III EORTC1325/KEYNOTE-054 trial on which the approval is based, more than three-quarters of these patients will not have cancer recurrence within one year after initial treatment
In the overall median follow-up of 42.
Fig.
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https://